Provider Newsflash
July 2026

FDA Recall – Baxter Cefazolin Dextrose Premix

Purpose of this communication:

We are writing to inform you that Baxter International Inc. is voluntarily recalling one lot of Baxter Cefazolin in Dextrose Injection, USP, 2 g/100 mL (20 mg/mL) Single-Dose Infusion Bag in 100 mL GALAXY Plastic Container, Frozen Premix, due to a report of particulate matter in the solution identified as cardboard. The affected lot is LD175708, expiration date 14-Feb-2027, NDC 0338-3508-41, product code 2G3508. The impacted product was distributed in the United States from March 25, 2025 through June 30, 2025. Use of the defective product has a reasonable probability of causing pulmonary emboli, blood vessel occlusions, phlebitis, systemic immune activation, organ dysfunction, and hemolysis. To date, Baxter has not received any reports of adverse events related to this issue.

What do I need to do?

- Please review the following recall notice here.
- Immediately review inventory for affected Baxter Cefazolin in Dextrose Injection, USP, product code 2G3508, lot LD175708, expiration date 14-Feb-2027, NDC 0338-3508-41; discontinue use, isolate/quarantine any impacted product, and arrange return or replacement through Baxter in accordance with facility process.
- Confirm whether any CareCentrix patients may have been affected by this recall and notify the CareCentrix Quality Department by faxing information to: 919-792-6718 Attn: Quality Department.

Thank you in advance for your cooperation and continued partnership.